Cultural recovery and determination of antimicrobial susceptibility in Helicobacter pylori by using commercial transport and isolation media

Infection

Volumn 33, Issue 2, 2005, Pages 77-81

  Yuen, B ^a   Zbinden, R ^b   Fried, M ^c   Bauerfeind, P ^c   Bernardi, M ^a  

^a GZO Hospital Wetzikon   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMOXICILLIN; ANTIINFECTIVE AGENT; CEFSULODIN; CLARITHROMYCIN; CYCLOHEXIMIDE; MACROLIDE; METRONIDAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; TRIMETHOPRIM; UREASE; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CONTROLLED STUDY; DUODENITIS; DUODENUM ULCER; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; NONHUMAN; STOMACH BIOPSY; STOMACH ULCER; UNIVERSITY HOSPITAL;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; SPECIMEN HANDLING;

EID: 17844405060     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-4071-y     Document Type: Article

References (24)

1. Suerbaum S, Michetti P: Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186.
2. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Phillips M, Waters TE, Sanderson CR: Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437-1441.
3. Hentschel E, Brandstätter G, Dragosics B, Hirschl AM, Nemec H, Schütze K,Taufer M, Wurzer H: Effect of ranitidine and amoxicillin plus metronidazole on eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-312.
4. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA:Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 28: 939-942.
5. Wilhelmsen I, Berstad A: Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori. Scand J Gastroenterol 1994; 29: 874-879.
6. De Boer WA, Tytgat GNJ: Regular review: treatment of Helicobacter pylori infection. BMJ 2000; 320: 31-34.
7. Mégraud F: Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 1998; 54: 207-216.
8. Buckley MJM, Xia HX, Hyde DM, Keane CT, O'Morain CA: Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42: 2111-2115.
9. Soltesz V, Zeeberg B, Wadstrom T: Optimal Survival of Helicobacter pylori under various transport conditions. J Clin Microbiol 1992; 30: 1453-1456.
10. Hachem C, Clarridge JE, Reddy R, Flamm R, Evans DG, Tanaka SK, Graham DY: Antimicrobial susceptibility testing of Helicobacter pylori. Diagn Microbiol Infect Dis 1996; 24: 37-41.
11. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial susceptibility testing; 10th informational supplement. NCCLS document M100-S10. NCCLS, Wayne, PA.
12. Maggi-Solca N, Valsangiacomo C, Piffaretti J-C: Prevalence of Helicobacter pylori resistant strains in the southern part of Switzerland. Clin Microbiol Infect 2000; 6: 38-40
13. Heep M, Scheibl K, Degrell A, Lehn N: Transport and storage of fresh and frozen gastric biopsy specimens for optimal recovery of Helicobacter pylori. J Clin Microbiol 1999; 37: 3764-3766.
14. Grove DI, McLeay RA, Byron KE, Koutsouridis G: Isolation of Helicobacter pylori after transport from a region laboratory of gastric biopsy specimens in saline, Portagerm pylori or cultured on chocolate agar. Pathology 2001; 33: 362-364.
15. Meyer JM, Sillimann NP, Wang W, Siepman NY, Sugg JE, Morris D, Zhang J, Bhattacharyya H, King EC, Hopkins RJ: Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136: 13-24.
16. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo M: Heli-cobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001; 15: 1473-1478.
17. European Study Group on antibiotic susceptibility of Helicobacter pylori: Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777-781.
18. Vakil N, Hahn B, McSorley D: Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Castroenterol 1998; 93: 1432-1435.
19. López-Brea M, Martinez MJ, Domingo D, Alarcon T: A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J Antimicrob Chemother 2001; 48: 295-297.
20. Hug BL, Rossi M: Ayear's review of bacterial pneumonia at the central hospital of Lucerne, Switzerland. Swiss Med Wkly 2001; 131: 687-692.
21. Malfertheiner P, Mégraud F, O'Morain C et al: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus report. Cut 1997; 41: 8-13.
22. Laheij RJF, Van Rossum LGM, Jansen JBMJ, Straatman H, Verbeek ALM: Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999; 13: 857-864.
23. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY: Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy; a metaanalytical approach. Dig Dis Sci 2000; 45: 68-76.
24. Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, Ciccaglione AF, Grossi L, Marzio L: Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 114: 1639-1643.